Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model.
Shih-Shih ChenJacqueline Claudia BarrientosGerardo FerrerMorgan King-RichardsYu-Ju ChenPriyadarshini RavichandranMichael IbrahimYasmine KiesoSheila WatersJeffery L KutokMarisa PelusoSujata SharmaDavid T WeaverJonathan A PachterKanti R RaiNicholas ChiorazziPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Our data define the mechanism of action whereby dual inhibition of PI3K-δ,γ affects CLL B-cell numbers and T and myeloid cell pro-leukemia functions and support the use of duvelisib as a valuable approach for therapeutic interventions, including for patients refractory to BTKi.
Keyphrases
- chronic lymphocytic leukemia
- end stage renal disease
- bone marrow
- acute myeloid leukemia
- induced apoptosis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- physical activity
- stem cells
- big data
- signaling pathway
- deep learning
- machine learning
- endoplasmic reticulum stress
- data analysis
- artificial intelligence
- pi k akt